Results 51 to 60 of about 2,519 (184)

The (Fab)ulous Destiny of Idarucizumab: Highlighting Its Interference with Urine Protein Immunofixation

TH Open, 2019
Idarucizumab is a humanized antigen binding fragment (Fab) of a recombinant anti-dabigatran monoclonal antibody (IgG1-kappa) that allows rapid and sustained reversal of dabigatran-induced anticoagulation in case of bleeding or urgent surgery.
Nicolas Gendron, Héloïse Flament, Elena Litvinova, Sofia Ortuno, Nadine Ajzenberg, Dorothée Faille   +5 more
doaj   +1 more source

Use of Idarucizumab for dabigatran reversal: Emergency department experience in two cases with subdural haematoma

Trauma Case Reports, 2018
Introduction: Idarucizumab is the first effective humanized monoclonal antibody fragment developed specifically as a reversal agent for dabigatran, a Direct Oral Anticoagulant. Despite recent trials demonstrating reversal of clinically relevant bleeding,
Gail Edwards, Cristina Roman, Rondhir Jithoo, Biswadev Mitra   +3 more
doaj   +1 more source

Global Use of Idarucizumab in Clinical Practice: Outcomes of the RE-VECTO Surveillance Program. [PDF]

, 2020
Idarucizumab was approved for the reversal of dabigatran in 2015. We investigated whether postapproval usage patterns of idarucizumab in a real-world setting reflect those observed in the pivotal trials.
Lane, Deirdre A, Reilly, Paul A., Fanikos, John, Reilly, Paul A, França, Lionel Riou, Murwin, Debra, Wowern, Fredrik von, Kermer, Pawel, Butcher, Ken, Gruenenfelder, Fredrik, Lane, Deirdre A., Tartakovsky, Igor   +11 more
core   +1 more source

The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination

, 2018
Idarucizumab, a humanized monoclonal antibody fragment (Fab), provides rapid and sustained reversal of dabigatran-mediated anticoagulation. Idarucizumab and dabigatran are mainly eliminated via the kidneys.
Markus Honickel, Joanne Van Ryn, Grottke, Oliver, Moschetti, Viktoria, Reilly, Paul, Honickel, Markus, Guanfa Gan, Gan, Guanfa, Viktoria Moschetti, Stephan Glund, Oliver Grottke, Glund, Stephan, Paul Reilly, van Ryn, Joanne   +13 more
core   +1 more source

Two Dabigatran Fast Reversals in a 4-month Period – a Case Report

European Journal of Case Reports in Internal Medicine, 2019
Introduction: Idarucizumab is available for immediate reversal of dabigatran-induced anticoagulation in life-threatening bleeding or urgent surgery in patients with non-valvular atrial fibrillation (nvAF).
Vítor Fagundes, Mari Mesquita
doaj   +1 more source

Systemic Thrombolysis in Acute Ischemic Stroke after Dabigatran Etexilate Reversal with Idarucizumab—A Case Report

, 2017
Introduction Idarucizumab is a reversal agent for dabigatran etexilate. By reversing the anticoagulating effect of dabigatran etexilate with idarucizumab (Praxbind), patients presenting with an acute ischemic stroke can now be eligible for thrombolysis ...
Tireli, Derya, Nordling, Mette Maria, Mette Maria Nordling, Jun He, Troels Wienecke, Wienecke, Troels, He, Jun, Derya Tireli   +7 more
core   +1 more source

Inside the ‘Black Box’ of Pharmaceuticalisation: NICE, the Permissive Principle and the Case of Anticoagulants

Sociology of Health &Illness, Volume 48, Issue 8, November 2026.
ABSTRACT Sociological interest in pharmaceuticalisation continues to grow, especially regarding the expansion of pharmaceutical use in society. This article presents the first major empirical study focusing on the directionality of pharmaceuticalisation by taking cost‐effectiveness assessment and regulation of anticoagulants in England by the National ...
John Abraham, Gowree Balendran
wiley   +1 more source

Idarucizumab: what should we know?

, 2018
BACKGROUND: Idarucizumab, a humanized monoclonal antibody fragment acting as specific antidote for dabigatran, is approved for reversing the dabigatran-associated possible bleeding from critical sites or bleeding persisting despite local post-procedure ...
Gesualdo M., Anna Maria Cortese, De Vito, F, Francesca Cortese, Rossella Carbonara, CARBONARA, ROSA, Cortese A. M., Carbonara S., Ciccone M. M., CORTESE, FRANCESCA, Zito A., CORTESE, ANNA MARIA, Annapaola Zito, CICCONE, Marco Matteo, CECERE, ANNAGRAZIA, Fiorella De Vito, GESUALDO, MICHELE, Cecere A., Michele Gesualdo, Annagrazia Cecere, Cortese F., CARBONARA, SANTA, Santa Carbonara, Marco Matteo Ciccone, Carbonara R., ZITO, ANNAPAOLA, Calculli G., Giacinto Calculli, De Vito F.   +28 more
core   +1 more source

Intravenous Thrombolysis After Reversal of Dabigatran With Idarucizumab in Acute Ischemic Stroke: A Case Report

Frontiers in Aging Neuroscience, 2021
Background: As there is a growing concern about the cerebral embolism events secondary to non-valvular atrial fibrillation (NVAF), novel oral anticoagulant (NOAC) has been more and more widely used as an anticoagulation treatment for the prevention of ...
Dan Xie, Xuefan Wang, Yao Li, Ruiling Chen, Yingying Zhao, Chunling Xu, Qian Zhang, Yongbo Zhang   +7 more
doaj   +1 more source

2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines (Part II) on Stroke Prevention in Atrial Fibrillation

Journal of Arrhythmia, Volume 42, Issue 5, October 2026.
ABSTRACT The 2026 Asia Pacific Heart Rhythm Society (APHRS) Guidelines represent the first comprehensive APHRS guidelines dedicated to the management of atrial fibrillation (AF) and comprise four parts covering epidemiology, detection/screening and integrated care; stroke prevention; rate and rhythm control; and lifestyle risk factor and comorbidity ...
Tze‐Fan Chao, Gregory Y. H. Lip, Yi‐Hsin Chan, So‐Ryoung Lee, Mingfang Li, Daehoon Kim, Ling Kuo, Ken Okumura, Hung‐Fat Tse, Eue‐Keun Choi, Minglong Chen, Boyoung Joung, Rungroj Krittayaphong, Melissa E. Middeldorp, Kyoko Soejima, Hui‐Nam Pak   +15 more
wiley   +1 more source